Pricing Log in Create free account

BioMarin Pharmaceutical Inc. (BMRN) vs ImmunityBio, Inc. (IBRX)

BioMarin Pharmaceutical Inc. and ImmunityBio, Inc. are both Biotechnology companies. BioMarin Pharmaceutical Inc. and ImmunityBio, Inc. are of similar size ($10.9B and $10.6B). ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; BioMarin Pharmaceutical Inc. trades at 144×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 11.2%. BioMarin Pharmaceutical Inc. has the higher net margin (2.14% vs −598.6%) and the higher return on invested capital (0.97% vs 0.00%). Across the 18 metrics below, BioMarin Pharmaceutical Inc. leads on 10 and ImmunityBio, Inc. on 8.

Valuation

Metric BMRN IBRX Biotechnology median
P/E 143.89 n/m 8.50
P/S 3.10 58.14 9.71
P/B 1.67 n/m 2.13
Price to free cash flow 14.59 n/m 20.82
EV/EBITDA 46.69 n/m 0.64
EV/Sales 4.08 63.56 9.21
Earnings yield 0.69% (10.57%) (33.15%)
Free cash flow yield 6.85% (2.99%) (25.50%)

Profitability

Metric BMRN IBRX Biotechnology median
Gross margin 76.12% 99.34% 65.16%
Operating margin 4.38% (151.88%) 0.00%
Net margin 2.14% (598.56%) 0.00%
Free cash flow margin 21.28% (173.76%) 0.00%
Return on equity 1.18% 122.85% (56.36%)
Return on assets 0.76% (192.58%) (48.04%)
Return on invested capital 0.97% 0.00% 0.00%

Growth

Metric BMRN IBRX Biotechnology median
Revenue growth (TTM) 11.20% 192.92% 6.02%
EPS growth (last fiscal year) (18.55%) 38.71% 30.26%
Revenue growth, 5-year CAGR 11.60% 184.76% 9.41%
Net income growth, 5-year CAGR (16.39%) 0.00% 0.00%

Health

Metric BMRN IBRX Biotechnology median
Debt to equity 0.66 (0.74) 0.00
Current ratio 2.39 5.72 4.72
Net debt to EBITDA (1.99) (0.97) 0.96

Dividend

Metric BMRN IBRX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BMRN IBRX Biotechnology median
Market cap 10.85b 10.60b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack